These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 36831629)

  • 1. Emerging Role of IGF-1 in Prostate Cancer: A Promising Biomarker and Therapeutic Target.
    Liu G; Zhu M; Zhang M; Pan F
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.
    Singh P; Alex JM; Bast F
    Med Oncol; 2014 Jan; 31(1):805. PubMed ID: 24338270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.
    Mancarella C; Casanova-Salas I; Calatrava A; Ventura S; Garofalo C; Rubio-Briones J; Magistroni V; Manara MC; López-Guerrero JA; Scotlandi K
    Oncotarget; 2015 Jun; 6(18):16611-22. PubMed ID: 25906745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway.
    Pandini G; Genua M; Frasca F; Vigneri R; Belfiore A
    Ann N Y Acad Sci; 2009 Feb; 1155():263-7. PubMed ID: 19250214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
    Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
    PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.
    Fahrenholtz CD; Greene AM; Beltran PJ; Burnstein KL
    Oncotarget; 2014 Oct; 5(19):9007-21. PubMed ID: 25344862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crk II silencing down-regulates IGF-IR and inhibits migration and invasion of prostate cancer cells.
    Dhupkar P; Zhao H; Mujoo K; An Z; Zhang N
    Biochem Biophys Rep; 2016 Dec; 8():382-388. PubMed ID: 28955980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.
    Fahrenholtz CD; Beltran PJ; Burnstein KL
    Mol Cancer Ther; 2013 Apr; 12(4):394-404. PubMed ID: 23348048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.
    Turney BW; Turner GD; Brewster SF; Macaulay VM
    BJU Int; 2011 May; 107(9):1488-99. PubMed ID: 20840329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of IGF/IGF-1R signaling in the regulation of cancer stem cells.
    Liu F; Ye S; Zhao L; Niu Q
    Clin Transl Oncol; 2024 Jun; ():. PubMed ID: 38865036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the IGF-1R in prostate and colorectal cancer: reasons behind trial failure and future directions.
    Tufail M; Wu C
    Ther Deliv; 2022 Mar; 13(3):167-186. PubMed ID: 35029130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression.
    Sroka IC; McDaniel K; Nagle RB; Bowden GT
    Prostate; 2008 Apr; 68(5):463-76. PubMed ID: 18196535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 15-lipoxygenase-1 expression upregulates and activates insulin-like growth factor-1 receptor in prostate cancer cells.
    Kelavkar UP; Cohen C
    Neoplasia; 2004; 6(1):41-52. PubMed ID: 15068670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma.
    Wan X; Yeung C; Heske C; Mendoza A; Helman LJ
    Neoplasia; 2015 Apr; 17(4):358-66. PubMed ID: 25925378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
    Nordstrand A; Bergström SH; Thysell E; Bovinder-Ylitalo E; Lerner UH; Widmark A; Bergh A; Wikström P
    Clin Exp Metastasis; 2017 Apr; 34(3-4):261-271. PubMed ID: 28447314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells.
    Fang J; Zhou Q; Shi XL; Jiang BH
    Carcinogenesis; 2007 Mar; 28(3):713-23. PubMed ID: 17065200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells.
    Ryan CJ; Zavodovskaya M; Youngren JF; Campbell M; Diamond M; Jones J; Shiry L; Allan G; Maddux BA; Goldfine ID
    Prostate; 2008 Aug; 68(11):1232-40. PubMed ID: 18491370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin-like growth factor signaling as a therapeutic target in pancreatic cancer.
    Rieder S; Michalski CW; Friess H; Kleeff J
    Anticancer Agents Med Chem; 2011 Jun; 11(5):427-33. PubMed ID: 21492074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells.
    Chen LH; Fang J; Sun Z; Li H; Wu Y; Demark-Wahnefried W; Lin X
    J Nutr; 2009 Apr; 139(4):653-9. PubMed ID: 19211828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
    Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
    Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.